Exclusive: Top neuroscientist Asa Abeliovich targets ALS, schizophrenia with new startup Leal after $1B Lilly buyout
After striking a billion-dollar deal for his last startup, Asa Abeliovich has built a new venture with even grander ambitions in treating some of the biggest neurological diseases.
Abeliovich exclusively told Endpoints News about Leal Therapeutics, his newest biotech that has operated in stealth for over two years. The Worcester, MA-headquartered startup raised a $39 million seed round in 2022, and is now raising its next financing to go into the clinic with its two lead drugs: LTX-001 in schizophrenia and LTX-002 in ALS. The company plans to file IND applications for both programs in the second half of 2024.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.